Trial: A Study of Disitamab Vedotin Alone or W…

Trial Details

Sponsor: Seagen, a wholly owned subsidiary of Pfizer (industry)

Phase: 2

Start date: May 3, 2022

Planned enrollment: 372

Trial ID: NCT04879329

More trial details at ClinicalTrials.gov

Show Summary from Sponsor

Investigational Drug AI Analysis

Show for: disitamab vedotin (RC48, Aidixi)

Overview

Disitamab vedotin (DV; RC48; Aidixi) is a HER2-directed antibody–drug conjugate developed for HER2-expressing solid tumors. It is approved for several indications in China but remains investigational in the United States; FDA orphan-drug designation does not constitute marketing approval. Clinical development includes urothelial, gastric/gastroesophageal-junction and breast cancers, including some tumors with low HER2 expression. (pubmed.ncbi.nlm.nih.gov)

Mechanism of action

DV consists of the humanized anti-HER2 antibody disitamab conjugated through a protease-cleavable linker to monomethyl auristatin E (MMAE). After HER2 binding and internalization, MMAE is released and inhibits microtubule polymerization, causing cell-cycle arrest and death. Membrane-permeable MMAE may also kill neighboring cells with lower HER2 expression—the proposed “bystander effect.” (pmc.ncbi.nlm.nih.gov)

Efficacy

First-line urothelial cancer: In a randomized phase III trial involving 484 patients with HER2-expressing advanced urothelial cancer, DV plus toripalimab improved median progression-free survival versus platinum chemotherapy (13.1 vs 6.5 months; HR 0.36) and median overall survival (31.5 vs 16.9 months; HR 0.54). Objective response rates were 76.1% and 50.2%, respectively. (nejm.org)
Previously treated urothelial cancer: A combined analysis of two single-arm phase II studies found an independently assessed response rate of 50.5% among 107 patients. Median response duration was 7.3 months, progression-free survival 5.9 months and overall survival 14.2 months. (ascopubs.org)
HER2-positive breast cancer with liver metastases: A randomized phase III trial found longer progression-free survival with DV than with lapatinib plus capecitabine (9.9 vs 4.9 months; HR 0.56) after prior trastuzumab and taxane therapy. (nature.com)
Advanced breast cancer, early-phase data: At 2 mg/kg every two weeks, response rates were 42.9% in HER2-overexpressing disease and 33.3% in HER2-low disease; median progression-free survival was 5.7 and 5.1 months, respectively. (pubmed.ncbi.nlm.nih.gov)
Gastric/gastroesophageal-junction cancer: In a phase I combination study, DV plus toripalimab produced a confirmed response rate of 43% overall and 50% at the recommended phase II dose; median progression-free survival was 6.2 months. These findings remain less definitive than randomized phase III evidence. (pubmed.ncbi.nlm.nih.gov)

Safety

Peripheral sensory neuropathy, leukopenia/neutropenia, fatigue or asthenia and elevated liver enzymes are recurring toxicities. In the previously treated urothelial-cancer studies, 54.2% experienced grade 3 or higher treatment-related adverse events, most notably peripheral neuropathy (18.7%) and neutropenia (12.1%). (ascopubs.org)

In first-line urothelial cancer, grade 3 or higher treatment-related events occurred in 55.1% with DV plus toripalimab versus 86.9% with chemotherapy. In the breast-cancer phase III trial, corresponding rates were 37.7% with DV and 36.0% with lapatinib–capecitabine. Rare serious events reported in combination studies include pneumonitis, including a treatment-related death. (nejm.org)

TrialFetch AI Analysis

Goal: Evaluate the antitumor activity and safety of disitamab vedotin, alone or with pembrolizumab, in locally advanced unresectable or metastatic urothelial carcinoma.

Patients: Patients have measurable urothelial carcinoma, generally with centrally confirmed HER2 expression (IHC 1+, 2+, or 3+). Cohorts include previously platinum-treated patients; previously untreated, platinum-eligible patients; patients in Japan previously treated with platinum, PD-(L)1 inhibition, and enfortumab vedotin; and patients previously treated with an enfortumab vedotin–containing regimen. ECOG performance status requirements vary by cohort, and baseline neuropathy is restricted.

Design: Multicenter, open-label, multi-cohort study with both nonrandomized groups and a randomized comparison of disitamab vedotin plus pembrolizumab versus disitamab vedotin alone in cohort C. Cohorts A and B distinguish HER2-positive and HER2-low tumors; cohorts D and E are Japan-only.

Treatments: Disitamab vedotin is given alone in cohorts A, B, D, and G, and alone or with pembrolizumab in cohort C; cohort E receives the combination. Disitamab vedotin is an investigational HER2-directed antibody–drug conjugate that delivers the microtubule inhibitor MMAE to HER2-expressing cells. In separate studies of previously treated urothelial carcinoma, it produced an approximately 51% independently assessed response rate; these are not results from the present trial. Pembrolizumab is a PD-1 inhibitor.

Outcomes: The primary efficacy endpoint for cohorts A, B, C, and G is confirmed objective response rate by blinded independent central review using RECIST 1.1. Primary assessments in the Japan-only cohorts D and E focus on adverse events, dose alterations, laboratory and cardiac findings, and pharmacokinetics. Secondary measures include response duration, progression-free and overall survival, disease control, safety, pharmacokinetics, and antidrug antibodies.

Burden on patient: Estimated burden is moderate to high. Participants require tumor tissue for central HER2 assessment, repeated imaging and safety evaluations, blood sampling for pharmacokinetics and immunogenicity, and visits for study-drug administration over potentially prolonged treatment. Visit and sampling schedules are not specified, and a new biopsy is not explicitly required.

Last updated: Sep 2026

Eligibility

Show Criteria

Inclusion Criteria:

Cohorts A and B

* Histopathologically-confirmed, locally-advanced, unresectable or metastatic urothelial cancer (LA/mUC), including UC originating from the renal pelvis, ureters, bladder, or urethra

* Participants must have received only 1 or 2 lines of prior systemic treatment for LA/mUC, including 1 line of platinum-containing chemotherapy

* At least one measurable lesion by investigator assessment based on RECIST version 1.1.

* HER2-expression status determined by the central laboratory to be IHC 1+, 2+ or 3+, in the provided tumor sample

* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1

Cohort C

* Histopathologically-confirmed LA/mUC, including UC originating from the renal pelvis, ureters, bladder, or urethra

* No prior systemic therapy for LA/mUC

* Neoadjuvant or adjuvant therapy, including PD-(L)1 inhibitors, is acceptable, if disease recurrence/progression occurred more than 12 months after the last dose of systemic therapy

* At least one measurable lesion by investigator assessment based on RECIST v1.1.

* Participant is eligible to receive cisplatin- or carboplatin- containing chemotherapy per investigator evaluation

* HER2-expression status determined by the central laboratory to be IHC 1+, 2+ or 3+, on the provided tumor tissue sample

* ECOG performance status of 0, 1, or 2

Cohort D

* Histopathologically-confirmed LA/mUC, including UC originating from the renal pelvis, ureters, bladder, or urethra

* Based on a participant's eligibility to receive treatment with standard of care therapies in Japan, participants must have received all of the following lines of therapy for LA/mUC:

* a. One prior line of platinum-containing chemotherapy.

* b. Prior therapy with PD-(L)1 inhibitors as (neo)adjuvant therapy, first-line maintenance therapy or as second line treatment.

* c. Prior enfortumab vedotin therapy.

* At least one measurable lesion by investigator assessment based on RECIST v1.1.

* ECOG performance status of 0 or 1

Cohort E

* Histopathologically-confirmed LA/mUC, including UC originating from the renal pelvis, ureters, bladder, or urethra

* No prior systemic therapy for LA/mUC

* Neoadjuvant or adjuvant therapy, including PD-(L)1 inhibitors, is acceptable, if disease recurrence/progression occurred more than 12 months after the last dose of systemic therapy.

* At least one measurable lesion by investigator assessment based on RECIST v1.1.

* Participant is eligible to receive cisplatin- or carboplatin- containing chemotherapy per investigator evaluation

* HER2-expression status determined by the central laboratory to be IHC 1+, 2+ or 3+, in the provided tumor sample

* ECOG performance status of 0 or 1

Cohort G

* Histopathologically-confirmed, locally-advanced, unresectable or metastatic urothelial cancer (LA/mUC), including UC originating from the renal pelvis, ureters, bladder, or urethra

* Participants must have received only 1 or 2 lines of prior systemic treatment for LA/mUC, including 1 line of therapy containing enfortumab vedotin as monotherapy or in combination with pembrolizumab

* The last administration of enfortumab vedotin must be 90 days from the start of study treatment. Intervening therapies are allowed between the final dose of enfortumab vedotin and the start of disitamab vedotin.

* At least one measurable lesion by investigator assessment based on RECIST version 1.1.

* HER2-expression status determined by the central laboratory to be IHC 1+, 2+ or 3+, in the provided tumor sample

* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1

Exclusion Criteria:

Cohorts A and B

* Known hypersensitivity to disitamab vedotin or any of their components

* Prior antitumor treatment (including chemotherapy, radiotherapy, targeted therapy, immunotherapy etc.) within 2 weeks of start of study (defined as Cycle 1 Day 1 for Cohorts A and B)

* Toxicity from a previous treatment has not returned to Grades 0 or 1 (except for Grade 2 alopecia)

* Prior MMAE-based ADCs (eg, enfortumab vedotin) or HER2-directed therapy

* Major surgery that has not fully recovered within 4 weeks prior to dose administration

* Peripheral sensory or motor neuropathy ≥ Grade 2 at baseline

Cohort C

* Known hypersensitivity to disitamab vedotin, pembrolizumab, or any of their components

* Prior antitumor treatment (including chemotherapy, radiotherapy, targeted therapy, immunotherapy etc.) within 2 weeks of start of study defined as Cycle 1 Day 1 for the single-arm part of Cohort C and as randomization date for the randomized part of Cohort C)

* Toxicity from a previous treatment has not returned to Grades 0 or 1 (except for Grade 2 alopecia)

* Prior MMAE-based ADCs (eg, enfortumab vedotin) or HER2-directed therapy

* Major surgery that has not fully recovered within 4 weeks prior to dose administration

* Peripheral sensory or motor neuropathy ≥ Grade 2 at baseline

* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study drug

* Participants who have previously received any prior treatment with an agent directed to another stimulatory or co-inhibitory T cell receptor (including but not limited to CD137 agonists, CAR-T cell therapy, CTLA-4 inhibitors, or OX-40 agonists) are excluded.

Cohort D

* Known hypersensitivity to disitamab vedotin or any of their components

* Prior antitumor treatment (including chemotherapy, radiotherapy, targeted therapy, immunotherapy etc.) within 2 weeks of start of study (defined as Cycle 1 Day 1 for Cohort D)

* Toxicity from a previous treatment has not returned to Grades 0 or 1 (except for Grade 2 alopecia)

* Prior HER2-directed therapy

* Any prior history of ≥ Grade 3 non-hematological AEs related to prior therapy

* Major surgery that has not fully recovered within 4 weeks prior to dose administration

* Peripheral sensory or motor neuropathy ≥ Grade 1 at baseline

Cohort E

* Known hypersensitivity to disitamab vedotin, pembrolizumab, or any of their components

* Prior antitumor treatment (including chemotherapy, radiotherapy, targeted therapy, immunotherapy etc.) within 2 weeks of start of study (defined as Cycle 1 Day 1 for Cohort E)

* Toxicity from a previous treatment has not returned to Grades 0 or 1 (except for Grade 2 alopecia)

* Any prior history of ≥ Grade 3 non-hematological AEs related to prior therapy

* Prior MMAE-based ADCs (eg, enfortumab vedotin) or HER2-directed therapy

* Major surgery that has not fully recovered within 4 weeks prior to dose administration

* Peripheral sensory or motor neuropathy ≥ Grade 1 at baseline

Cohort G

* Known hypersensitivity to disitamab vedotin or any of their components

* Prior antitumor treatment (including chemotherapy, radiotherapy, targeted therapy, immunotherapy etc.) within 2 weeks of start of study (defined as Cycle 1 Day 1 for Cohort G)

* Toxicity from a previous treatment has not returned to Grades 0 or 1 (except for Grade 2 alopecia)

* Prior HER2-directed therapy

* Major surgery that has not fully recovered within 4 weeks prior to dose administration

* Peripheral sensory or motor neuropathy ≥ Grade 2 at baseline

There are additional inclusion and exclusion criteria. The study center will determine if criteria for participation are met.

Sites (223)

Sort by distance to:

Centro Medico Austral

CABA, C1019ABS, Argentina

No email / No phone

Status: Recruiting

Centro Oncologico Korben

Caba, ZC 1426, Argentina

No email / No phone

Status: Recruiting

Hospital Aleman

Buenos Aires, C1118AAT, Argentina

No email / No phone

Status: Recruiting

Hospital Sirio Libanes - Buenos Aires

Buenos Aires, ZC 1419, Argentina

No email / No phone

Status: Recruiting

Instituto Medico Especializado Alexander Fleming

Buenos Aires, C1426ANZ, Argentina

No email / No phone

Status: Recruiting

Instituto Oncologico de Cordoba

Córdoba, X5000, Argentina

No email / No phone

Status: Recruiting

Clinica Viedma

Viedma, Río Negro Province, R8500ACE, Argentina

No email / No phone

Status: Recruiting

Lyell McEwin Hospital

Elizabeth Vale, 5112, Australia

No email / No phone

Status: Recruiting

Cancer Care Research Pty Ltd (trading as GenesisCare)

Alexandria, New South Wales, 2015, Australia

No email / No phone

Status: Recruiting

GenesisCare - North Shore

St Leonards, New South Wales, 2065, Australia

No email / No phone

Status: Recruiting

Macquarie University

Sydney, New South Wales, 2109, Australia

No email / No phone

Status: Recruiting

Mater Cancer Care Centre, Mater Misericordiae Limited

South Brisbane, Queensland, QLD 4101, Australia

No email / No phone

Status: Recruiting

Metro South Hospital and Health Service

Brisbane, Queensland, 4102, Australia

No email / No phone

Status: Recruiting

Peninsula & South Eastern Haematology and Oncology Group

Frankston, Victoria, 3199, Australia

No email / No phone

Status: Recruiting

Arthur J.E. Child Comprehensive Cancer Centre

Calgary, Alberta, T3N 4N1, Canada

No email / No phone

Status: Recruiting

BC Cancer - Vancouver

Vancouver, British Columbia, V5Z 4E6, Canada

No email / No phone

Status: Recruiting

BC Cancer - Vancouver Fairmont Medical Building

Vancouver, British Columbia, V5Z 1H7, Canada

No email / No phone

Status: Recruiting

CancerCare Manitoba

Winnipeg, Manitoba, R3E 0V9, Canada

No email / No phone

Status: Recruiting

Jewish General Hospital

Montreal, Quebec, H3T 1E2, Canada

No email / No phone

Status: Recruiting

Oncovida SA

Providencia, 8320000, Chile

No email / No phone

Status: Recruiting

Centro de Estudios Clínicos IC La Serena Research

La Serena, Coquimbo Region, 1720430, Chile

No email / No phone

Status: Recruiting

Pontificia Universidad Catolica de Chile

Santiago, Providencia, 8330032, Chile

No email / No phone

Status: Recruiting

Ankara Universitesi Tip Fakultesi Hastaneleri - Cebeci Arastirma ve Uygulama Hastanesi

Ankara, 06620, Turkey (Türkiye)

No email / No phone

Status: Recruiting

Izmir Ekonomi Universitesi Medical Point Hastanesi

Izmir, 35575, Turkey (Türkiye)

No email / No phone

Status: Recruiting

T.C. Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi

Istanbul, 34722, Turkey (Türkiye)

No email / No phone

Status: Recruiting

Trakya Universitesi Tip Fakultesi Hastanesi (Saglik Arastirma ve Uygulama Merkezi)

Edirne, 22030, Turkey (Türkiye)

No email / No phone

Status: Recruiting

Barts Health NHS Trust, St Bartholomew's Hospital

London, EC1A 7BE, United Kingdom

No email / No phone

Status: Recruiting

Cambridge University Hospitals NHS Foundation Trust

Cambridge, CB2 0QQ, United Kingdom

No email / No phone

Status: Recruiting

Charing Cross Hospital

London, W6 8RF, United Kingdom

No email / No phone

Status: Recruiting

Guy's Hospital

London, SE1 9RT, United Kingdom

No email / No phone

Status: Recruiting

The Clatterbridge Cancer Centre NHS Foundation Trust, The Clatterbridge Cancer Centre - Wirral

Merseyside, CH63 4JY, United Kingdom

No email / No phone

Status: Recruiting

Beatson West of Scotland Cancer Centre

Glasgow, Scotland, G12 0YN, United Kingdom

No email / No phone

Status: Recruiting

Banner Gateway Medical Center

Gilbert, Arizona, 85234, United States

No email / No phone

Status: Recruiting

Banner MD Anderson Cancer Center

Gilbert, Arizona, 85234, United States

No email / No phone

Status: Recruiting

Beverly Hills Multi-Specialties Practice

Beverly Hills, California, 90211, United States

No email / No phone

Status: Recruiting

Chao Family Comprehensive Cancer Center and Ambulatory Care

Irvine, California, 92612, United States

No email / No phone

Status: Recruiting

Diagnostic Medical Group of Southern California (Radiology)

San Gabriel, California, 91776, United States

No email / No phone

Status: Recruiting

Foothill Cardiology Glendora

Glendora, California, 91741, United States

No email / No phone

Status: Recruiting

Foothill Cardiology Pasadena

Pasadena, California, 91105, United States

No email / No phone

Status: Recruiting

Foothill Cardioology

Arcadia, California, 91007, United States

No email / No phone

Status: Recruiting

Kaiser Permanente Alton/Sand Canyon Medical Offices

Irvine, California, 92618, United States

No email / No phone

Status: Recruiting

Kaiser Permanente Anaheim Kraemer Medical Offices

Anaheim, California, 92806, United States

No email / No phone

Status: Recruiting

Kaiser Permanente Baldwin Park Medical Center

Baldwin Park, California, 91706, United States

No email / No phone

Status: Recruiting

Kaiser Permanente Bellflower Medical Offices

Bellflower, California, 90706, United States

No email / No phone

Status: Recruiting

Kaiser Permanente Fontana Medical Center

Fontana, California, 92335, United States

No email / No phone

Status: Recruiting

Kaiser Permanente Los Angeles Medical Offices

Los Angeles, California, 90027, United States

No email / No phone

Status: Recruiting

Kaiser Permanente Ontario Medical Center

Ontario, California, 91761, United States

No email / No phone

Status: Recruiting

Kaiser Permanente Panorama City Medical Center, Medical Offices 3

Panorama City, California, 91402, United States

No email / No phone

Status: Recruiting

Kaiser Permanente Riverside Medical Center

Riverside, California, 92505, United States

No email / No phone

Status: Recruiting

Kaiser Permanente San Diego Mission Road (Regulatory and Lab Supplies)

San Diego, California, 92108, United States

No email / No phone

Status: Recruiting

Kaiser Permanente San Marcos Medical Offices

San Marcos, California, 92078, United States

No email / No phone

Status: Recruiting

Kaiser Permanente South Bay Medical center

Harbor City, California, 90710, United States

No email / No phone

Status: Recruiting

Kaiser Permanente West Los Angeles Medical Center

Los Angeles, California, 90034, United States

No email / No phone

Status: Recruiting

Kaiser Permanente Woodland Hills Medical Center

Woodland Hills, California, 91367, United States

No email / No phone

Status: Recruiting

Kaiser Permanente Zion Medical Center

San Diego, California, 92120, United States

No email / No phone

Status: Recruiting

Newport Diagnostics Center (Radiology)

Newport Beach, California, 92660, United States

No email / No phone

Status: Recruiting

Providence Saint Joseph Medical Center

Burbank, California, 91505, United States

No email / No phone

Status: Recruiting

Ronald Reagan UCLA Medical Center, Drug Information Center

Los Angeles, California, 90095, United States

No email / No phone

Status: Recruiting

Sierra Vista Regional Medical Center

San Luis Obispo, California, 93405, United States

No email / No phone

Status: Recruiting

Southern California Heart Centers

San Gabriel, California, 91776, United States

No email / No phone

Status: Recruiting

Southern California Heart Specialists

Pasadena, California, 91105, United States

No email / No phone

Status: Recruiting

Southern California Permanente Medical Group (SCPMG)

Riverside, California, 92505, United States

No email / No phone

Status: Recruiting

Twin Cities Community Hospital

Templeton, California, 93465, United States

No email / No phone

Status: Recruiting

UC Irvine Health

Orange, California, 92868, United States

No email / No phone

Status: Recruiting

UCLA Burbank Cardiology

Burbank, California, 91505, United States

No email / No phone

Status: Recruiting

UCLA Cardiovascular Center

Los Angeles, California, 90095, United States

No email / No phone

Status: Recruiting

UCLA Downtown Los Angeles Primary & Specialty Care

Los Angeles, California, 90017, United States

No email / No phone

Status: Recruiting

UCLA Encino Specialty Care (Radiology)

Encino, California, 91436, United States

No email / No phone

Status: Recruiting

UCLA Hematology Oncology

Los Angeles, California, 90095, United States

No email / No phone

Status: Recruiting

UCLA Hematology Oncology - Porter Ranch

Porter Ranch, California, 91326, United States

No email / No phone

Status: Recruiting

UCLA Hematology-Oncology Clinic - Santa Clarita

Valencia, California, 91355, United States

No email / No phone

Status: Recruiting

UCLA Hematology/ Oncology- Pasadena

Pasadena, California, 91105, United States

No email / No phone

Status: Recruiting

UCLA Hematology/Oncoclogy-Encino

Encino, California, 91436, United States

No email / No phone

Status: Recruiting

UCLA Hematology/Oncology - Burbank

Burbank, California, 91505, United States

No email / No phone

Status: Recruiting

UCLA Hematology/Oncology - San Luis Obispo

San Luis Obispo, California, 93401, United States

No email / No phone

Status: Recruiting

UCLA Hematology/Oncology - Santa Monica

Santa Monica, California, 90404, United States

No email / No phone

Status: Recruiting

UCLA Hematology/Oncology - Torrance

Torrance, California, 90505, United States

No email / No phone

Status: Recruiting

UCLA Hematology/Oncology - Ventura

Ventura, California, 93003, United States

No email / No phone

Status: Recruiting

UCLA Hematology/Oncology - Westlake

Westlake Village, California, 91361, United States

No email / No phone

Status: Recruiting

UCLA Montecito Primary & Specialty Care

Montecito, California, 93108, United States

No email / No phone

Status: Recruiting

UCLA Porter Ranch Primary & Specialty Care

Porter Ranch, California, 91326, United States

No email / No phone

Status: Recruiting

UCLA Santa Clarita Primary & Specialty Care

Valencia, California, 91355, United States

No email / No phone

Status: Recruiting

UCLA Santa Monica Cardiology

Los Angeles, California, 90404, United States

No email / No phone

Status: Recruiting

UCLA Simi Valley Alamo Specialty Care

Simi Valley, California, 93065, United States

No email / No phone

Status: Recruiting

UCLA Thousand Oaks Primary & Specialty Care

Thousand Oaks, California, 91360, United States

No email / No phone

Status: Recruiting

UCLA Torrance Lomita Specialty Care

Torrance, California, 90505, United States

No email / No phone

Status: Recruiting

UCLA Ventura Cardiology

Ventura, California, 93003, United States

No email / No phone

Status: Recruiting

UCLA Westwood Specialty Care

Los Angeles, California, 90095, United States

No email / No phone

Status: Recruiting

UCSF Cancer Center MZ Phlebotomy

San Francisco, California, 94115, United States

No email / No phone

Status: Recruiting

UCSF Investigational Drugs Pharmacy

San Francisco, California, 94158, United States

No email / No phone

Status: Recruiting

UCSF Mount Zion Phlebotomy

San Francisco, California, 94115, United States

No email / No phone

Status: Recruiting

UCSF Parnassus Phlebotomy

San Francisco, California, 94143, United States

No email / No phone

Status: Recruiting

University of California, San Francisco

San Francisco, California, 94158, United States

No email / No phone

Status: Recruiting

University of California, San Francisco | HDFCCC - Hematopoietic Malignancies

San Francisco, California, 94158, United States

No email / No phone

Status: Recruiting

Florida Cancer Specialists

Bonita Springs, Florida, 34135, United States

No email / No phone

Status: Recruiting

Florida Cancer Specialists

Bradenton, Florida, 34205, United States

No email / No phone

Status: Recruiting

Florida Cancer Specialists

Bradenton, Florida, 34211, United States

No email / No phone

Status: Recruiting

Florida Cancer Specialists

Cape Coral, Florida, 33909, United States

No email / No phone

Status: Recruiting

Florida Cancer Specialists

Fleming Island, Florida, 32003, United States

No email / No phone

Status: Recruiting

Florida Cancer Specialists

Fort Myers, Florida, 33905, United States

No email / No phone

Status: Recruiting

Florida Cancer Specialists

Fort Myers, Florida, 33908, United States

No email / No phone

Status: Recruiting

Florida Cancer Specialists

N. Venice, Florida, 34275, United States

No email / No phone

Status: Recruiting

Florida Cancer Specialists

Naples, Florida, 34102, United States

No email / No phone

Status: Recruiting

Florida Cancer Specialists

Port Charlotte, Florida, 33980, United States

No email / No phone

Status: Recruiting

Florida Cancer Specialists

Sarasota, Florida, 34232, United States

No email / No phone

Status: Recruiting

Florida Cancer Specialists

Tallahassee, Florida, 32308, United States

No email / No phone

Status: Recruiting

Florida Cancer Specialists

Venice, Florida, 34285, United States

No email / No phone

Status: Recruiting

Florida Cancer Specialists

Venice, Florida, 34292, United States

No email / No phone

Status: Recruiting

Florida Cancer Specialists Sarasota Memorial Hospital (SAD)

Sarasota, Florida, 34239, United States

No email / No phone

Status: Recruiting

Moffitt Cancer Center

Tampa, Florida, 33612, United States

No email / No phone

Status: Recruiting

Moffitt Cancer Center McKinley Hospital

Tampa, Florida, 33612, United States

No email / No phone

Status: Recruiting

Accellacare - Deerfield

Deerfield, Illinois, 60015, United States

No email / No phone

Status: Recruiting

The University of Chicago Medicine Center for Advanced Care Orland Park

Orland Park, Illinois, 60462, United States

No email / No phone

Status: Recruiting

UChicago Medicine - River East

Chicago, Illinois, 60611, United States

No email / No phone

Status: Recruiting

UChicago Medicine Ingalls Memorial

Harvey, Illinois, 60426, United States

No email / No phone

Status: Recruiting

UChicago Medicine at Ingalls - Flossmoor

Flossmoor, Illinois, 60422, United States

No email / No phone

Status: Recruiting

UChicago Medicine at Ingalls - Tinley Park

Tinley Park, Illinois, 60477, United States

No email / No phone

Status: Recruiting

University of Chicago Comprehensive Cancer Center at Silver Cross Hospital

New Lenox, Illinois, 60451, United States

No email / No phone

Status: Recruiting

University of Chicago Medical Center

Chicago, Illinois, 60637, United States

No email / No phone

Status: Recruiting

UMass Memorial Medical Center

Worcester, Massachusetts, 01655, United States

No email / No phone

Status: Recruiting

University of Massachusetts Chan Medical School

Worcester, Massachusetts, 01655, United States

No email / No phone

Status: Recruiting

Cancer & Hematology Centers of Western Michigan, PC- Kit Storage

Grand Rapids, Michigan, 49546, United States

No email / No phone

Status: Recruiting

Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion)

Detroit, Michigan, 48202, United States

No email / No phone

Status: Recruiting

Karmanos Cancer Institute

Detroit, Michigan, 48201, United States

No email / No phone

Status: Recruiting

Karmanos Cancer Institute Weisberg Cancer Treatment Center

Farmington Hills, Michigan, 48334, United States

No email / No phone

Status: Recruiting

Karmanos Cancer Institute at McLaren Greater Lansing

Lansing, Michigan, 48910, United States

No email / No phone

Status: Recruiting

The Cancer & Hematology Centers

Holland, Michigan, 49424, United States

No email / No phone

Status: Recruiting

The Cancer & Hematology Centers

Norton Shores, Michigan, 49444, United States

No email / No phone

Status: Recruiting

The Cancer & Hematology Centers

Grand Rapids, Michigan, 49546, United States

No email / No phone

Status: Recruiting

The Cancer & Hematology Centers

Grand Rapids, Michigan, 49503, United States

No email / No phone

Status: Recruiting

The Cancer & Hematology Centers

Big Rapids, Michigan, 49307, United States

No email / No phone

Status: Recruiting

MSK Basking Ridge

Basking Ridge, New Jersey, 07920, United States

No email / No phone

Status: Recruiting

MSK Bergen

Montvale, New Jersey, 07645, United States

No email / No phone

Status: Recruiting

MSK Monmouth

Middletown, New Jersey, 07748, United States

No email / No phone

Status: Recruiting

Evelyn H. Lauder Breast and Imaging Centre (BAIC)

New York, New York, 10065, United States

No email / No phone

Status: Recruiting

Icahn School of Medicine at Mount Sinai

New York, New York, 10029, United States

No email / No phone

Status: Recruiting

MSK Commack

Commack, New York, 11725, United States

No email / No phone

Status: Recruiting

MSK Wesrchester

Harrison, New York, 10604, United States

No email / No phone

Status: Recruiting

MSK nassau

Uniondale, New York, 11553, United States

No email / No phone

Status: Recruiting

Memorial Sloan Kattering Cancer Centre- Investigational Drug Service Pharmacy

Long Island City, New York, 11101, United States

No email / No phone

Status: Recruiting

Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street).

New York, New York, 10021, United States

No email / No phone

Status: Recruiting

Memorial Sloan Kettering Cancer Center - Main Campus

New York, New York, 10065, United States

No email / No phone

Status: Recruiting

Sidney Kimmel Center for Prostate and Urological Cancers - Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States

No email / No phone

Status: Recruiting

Atrium Health Cabarrus (biopsy only)

Concord, North Carolina, 28025, United States

No email / No phone

Status: Recruiting

Atrium Health Mercy (biopsy only)

Charlotte, North Carolina, 28207, United States

No email / No phone

Status: Recruiting

Atrium Health Union (biopsy only)

Monroe, North Carolina, 28112, United States

No email / No phone

Status: Recruiting

Atrium Health University City (biopsy only)

Charlotte, North Carolina, 28262, United States

No email / No phone

Status: Recruiting

Carolinas Medical Center (biopsy only)

Charlotte, North Carolina, 28203, United States

No email / No phone

Status: Recruiting

Carolinas Medical Center Investigational Drug Services

Charlotte, North Carolina, 28204, United States

No email / No phone

Status: Recruiting

Levine Cancer Institute

Charlotte, North Carolina, 28204, United States

No email / No phone

Status: Recruiting

Levine Cancer Institute - Ballantyne

Charlotte, North Carolina, 28277, United States

No email / No phone

Status: Recruiting

Levine Cancer Institute Concord

Concord, North Carolina, 28025, United States

No email / No phone

Status: Recruiting

Levine Cancer Institute University

Charlotte, North Carolina, 28262, United States

No email / No phone

Status: Recruiting

Levine Cancer Institute- Gaston

Gastonia, North Carolina, 28054, United States

No email / No phone

Status: Recruiting

OSU Wexner Medical Center & James Cancer Hospital

Columbus, Ohio, 43210, United States

No email / No phone

Status: Recruiting

OSU Wexner Medical Center, Investigational Drug Services

Columbus, Ohio, 43210, United States

No email / No phone

Status: Recruiting

Ohio State University

Columbus, Ohio, 43210, United States

No email / No phone

Status: Recruiting

Ohio State University Hospital

Columbus, Ohio, 43210, United States

No email / No phone

Status: Recruiting

The James Cancer Hospital & Solove Research Institute at The OSU Comprehensive Cancer Center

Columbus, Ohio, 43210, United States

No email / No phone

Status: Recruiting

The James Outpatient Care West Campus

Columbus, Ohio, 43221, United States

No email / No phone

Status: Recruiting

University Hospitals Cleveland Medical Center

Cleveland, Ohio, 44106, United States

No email / No phone

Status: Recruiting

OU Health Stephenson Cancer Center

Oklahoma City, Oklahoma, 73104, United States

No email / No phone

Status: Recruiting

OU Medical Center

Oklahoma City, Oklahoma, 73104, United States

No email / No phone

Status: Recruiting

University of Tennessee Medical Center

Knoxville, Tennessee, 37920, United States

No email / No phone

Status: Recruiting

The University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States

No email / No phone

Status: Recruiting

Inova Schar Cancer Institute

Fairfax, Virginia, 22031, United States

No email / No phone

Status: Recruiting

Fred Hutchinson Cancer Center

Seattle, Washington, 98109, United States

No email / No phone

Status: Recruiting

Harborview Medical Center

Seattle, Washington, 98104, United States

No email / No phone

Status: Recruiting

University of Washington Medical Center

Seattle, Washington, 98195, United States

No email / No phone

Status: Recruiting

Froedtert Hospital/Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States

No email / No phone

Status: Recruiting